Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
Small Ball Wins Games – Combination Therapy for Goal Attainment
Matthew Malachowski, Pharm. D., MHA
Extra Innings – Sustaining Victory Beyond the First Game
Turning the Double Play – Comprehensive Secondary Prevention
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS
Anjali Owens, MD
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
Is CKD-aP Hiding in Your Dialysis Center?
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Elevating CKD-aP Care: New Frontier
Lucio Manenti, MD, PhD